Hormonal
High body mass index (BMI) and visceral adiposity are strong independent risk factors for the development and progression of chronic kidney disease (CKD), end-stage renal disease (ESRD), and obesity-related glomerulopathy (ORG).
Maintaining a healthy weight is one of the most effective ways to protect your kidneys. High body weight puts direct mechanical and hormonal stress on your kidneys, increasing the risk of kidney failure. If you are overweight, even modest weight loss through diet and exercise can significantly lower your risk of developing kidney disease or slow its progression.
A high body mass index is one of the strongest risk factors for new-onset chronic kidney disease... The incidence of obesity-related glomerulopathy has increased 10-fold in recent years.
Why this rating
Based on numerous large population-based cohort studies and meta-analyses cited in the text.
Source
Obesity and Kidney Disease: Hidden Consequences of the Epidemic
Csaba P. Kövesdy et al. · World Journal of Nephrology and Urology · 2017
DOI 10.14740/wjnu281e
More from this paper
- Obesity causes kidney damage through direct mechanisms including glomerular hyperfiltration, increased intraglomerular pressure, and the endocrine activity of adipose tissue, independent of diabetes and hypertension.Good
- Weight loss interventions, including lifestyle changes and bariatric surgery, reduce blood pressure, glomerular hyperfiltration, and proteinuria in obese patients with CKD.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →